- Open Access
Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells
© Mathews et al; licensee BioMed Central Ltd. 2010
- Received: 5 April 2010
- Accepted: 7 October 2010
- Published: 7 October 2010
Recently, much attention has been focused on gaining a better understanding of the different populations of cells within a tumor and their contribution to cancer progression. One of the most commonly used methods to isolate a more aggressive sub-population of cells utilizes cell sorting based on expression of certain cell adhesion molecules. A recently established method we developed is to isolate these more aggressive cells based on their properties of increased invasive ability. These more invasive cells have been previously characterized as tumor initiating cells (TICs) that have a stem-like genomic signature and express a number of stem cell genes including Oct3/4 and Nanog and are more tumorigenic compared to their 'non-invasive' counterpart. They also have a profile reminiscent of cells undergoing a classic pattern of epithelial to mesenchymal transition or EMT. Using this model of invasion, we sought to investigate which genes are under epigenetic control in this rare population of cells. Epigenetic modifications, specifically DNA methylation, are key events regulating the process of normal human development. To determine the specific methylation pattern in these invasive prostate cells, and if any developmental genes were being differentially regulated, we analyzed differences in global CpG promoter methylation.
Differentially methylated genes were determined and select genes were chosen for additional analyses. The non-receptor tyrosine kinase BMX and transcription factor SOX1 were found to play a significant role in invasion. Ingenuity pathway analysis revealed the methylated gene list frequently displayed genes from the IL-6/STAT3 pathway. Cells which have decreased levels of the targets BMX and SOX1 also display loss of STAT3 activity. Finally, using Oncomine, it was determined that more aggressive metastatic prostate cancers in humans also have higher levels of both Stat3 and Sox1.
Using this method we can begin to understand which genes are epigenetically regulated in the invasive population compared to the bulk tumor cells. These aggressive sub-populations of cells may be linked to the cancer stem cell hypothesis, making their patterns of epigenetic regulation very attractive for biomarker analysis.
- Prostate Cancer
- LNCaP Cell
- Ingenuity Pathway Analysis
- DU145 Cell
- Invasive Population
Cancer is defined as uncontrolled cell growth resulting from genetic mutations or exposure to environmental carcinogens that alter normal regulation. If the cancer is aggressive in nature, invasion of local tissues near the primary tumor site as well as distant metastasis can occur. Current treatment regimens almost always involve a form of surgery to remove the primary tumor and systemic chemotherapy with localized radiation. However, aggressive cells can remain in the body and evade treatment with these conventional therapies. Additionally, it has been well documented that only a small fraction of epithelial tumor cells have the ability to form colonies in vitro or to initiate a new tumor upon injection into a host in vivo[1–6]. In order to study the epigenetic regulation of these aggressive cells, we chose to study an invasive population of prostate cancer cells. We and others have developed a novel method for the isolation of these cells from bulk tumor cell populations using Matrigel [7, 8]. These cells have a stem-like phenotype  and exist within both established cell lines (LNCaP and DU145) and in cells isolated from primary prostate cancer tissue (PCSC1-3). The invasive cells have been characterized as undergoing an epithelial to mesenchymal transition (EMT) during the process of invasion, and are also highly tumorigenic when injected into mice . They demonstrate increases in the stem cell regulators CD44, CD133, Bmi1, Nanog, and Sonic hedgehog (Shh), as well as increased expression in mesenchymal markers such as Vimentin and Tgfβ-1, and a decrease in the epithelial marker E-cadherin (CDH1). Over the last few years this hypothesis of EMT and cancer progression has been widely supported in models of not only prostate cancer, but also within the breast, colon, lung and pancreas [9–16]. The idea that the same cells which are undergoing the EMT may also be a population of cells called cancer stem cells or CSCs is a relativity new concept.
It is becoming more evident that CSCs are not governed by the same type of genetic regulation as normal stem cells, and arguably in solid tumors may be an epithelial cell that has up-regulated pathways that have been previously observed in true stem cells. In order to determine the epigenetic profile of these invasive prostate cancer cells, we isolated DNA and performed a very sensitive MeDIP (methylated DNA immunoprecipitation) assay coupled with Agilent's 244 K Human Promoter Tiling Arrays. This allowed for an in-depth analysis of the methylation status within promoter elements, upstream as well as down, in these cells. Differences between the invaded (more stem-like) and non-invaded cells, as well as the bulk tumor cell line (parental cells) were compared. In our analysis, the LNCaP and DU145 cell lines were used, as well as confirmation analysis in two primary prostate cancer cell lines (PCSC1 and PCSC2).
A unique set of genes were found to be expressed in the invasive cells, yet methylated in the non-invasive cells and parental cell lines. This included genes involved in embryonic and tissue/organ development, and specifically in neurogenesis including bone marrow X kinase (Bmx), Iroquois homeobox 3 (Irx3), Sine oculis homeobox homolog 1 (Six1) and Sex determining region-Y-box 1 (Sox1). Using the available online expression databases in Oncomine, it was determined that Sox1 plays a significant role in prostate cancer progression and metastasis. Furthermore, Ingenuity pathway analysis determined that the set of differentially methylated genes are involved in cellular functions such as cell-to-cell interaction and cell morphology, as well as development of the hematological system and cancer. The most intriguing data identified many of the methylated targets as members of the IL-6/STAT3 signaling pathway. Further investigation demonstrated that Stat3 was increased in these invasive cells, and cells infected with an shRNA against either BMX or SOX1 resulted in decreased levels of activated STAT3. However, only the differentially methylated Sox1 directly interacts with STAT3. Thus, in our model SOX1 plays a critical role in regulating invasive prostate cancer cells. These aggressive sub-populations of cells may be linked to the cancer stem cell hypothesis, making their patterns of epigenetic regulation very attractive for biomarker analysis.
Cell Lines and Reagents
LNCaP and DU145 human prostate cancer cell lines were obtained from ATCC and cultured accordingly (Manassas, VA). Primary human prostate cancer cells (PCSC1-2)  were acquired from Celprogen (San Pedro, CA) and maintained as recommended using specific coated culture plates and defined media. Human bone marrow derived mesenchymal stem cells (hMSCs) were obtained from Lonza (Gaithersburg, MD) and maintained using their recommended conditions. The cultures were maintained in 5% CO2 air at 37°C. Human serum was obtained from Gemini Bioproducts (West Sacramento, CA). The following inhibitors were also used: Anti-human IL-6 antibody (R&D Systems, Minneapolis, MN), PI3K inhibitor LY294002 (Cell Signaling, Danvers, MA), Tec Kinase inhibitor LFM-A13 (Tocris, Ellisville, MO), MEK inhibitor PD98059 (Gibco, Carlsbad, CA), JAK inhibitor AG490 (Gibco), and STAT3 inhibitor Stattic (Sigma Aldrich, St. Louis, MO).
Matrigel Invasion Assay
Matrigel-coated 24-well inserts (8 μM pore size) and non-coated control inserts purchased from BD Biosciences (Palo Alto, CA) were used according to manufacturer's instructions. A range of 20,000-100,000 cells were seeded for the invasion (higher for less invasive LNCaP cells). Cells were seeded in serum-free RPMI and migrated toward media specific for stem cells (SCM) containing DMEM/F12 with human supplementation of 10 ng/mL bFGF, 20 ng/mL EGF and 5 μg/mL insulin along with 0.4% BSA (each from Sigma, St. Louis, MO). Routine invasion assays were performed for 24 hours and then stained with the Diffi-Quick Staining kit (Dade Behring, Deerfield, IL). Three to five microscopic fields (20×) were photographed and counted for each sample. Percent invasion was calculated as average number of cells/field (Matrigel) divided by average number of cells/field (control insert). Values were averaged from 2-5 independent experiments. For the isolation of cells from top 'non-invading' and bottom 'invading' cells, parallel invasion chambers were setup. For non-invading cells, the bottom of the membrane was scrubbed with a cotton swab and cells on top were harvested using 500 μL of Accutase (eBioscience, San Diego, CA) incubated at 37°C for 5 minutes. To obtain the invading cells, the top of the membrane was scrubbed with a cotton swab and the chambers were placed into another 24- well plate containing 500 μL of Accutase incubated at 37°C for 5 minutes.
Matrigel invasion assays were carried out as previously described. For the isolation of DNA from both non-invasive and invasive cells the DNeasy kit from Qiagen (Valencia, CA) was used and parallel invasion chambers were setup. For non-invading cells, the bottom of the membrane was scrubbed with a cotton swab and cells on top were trypsinized and harvested in 200 μL of PBS followed by the direct addition of lysis buffer or stored at -80°C. For bottom 'invading cells' the top of the membrane was scrubbed with a cotton swab and the membrane was removed and placed directly into lysis buffer or stored at -80°C until needed. A modified version of Agilent's (Santa Clara, CA) protocol for Mammalian ChIP on ChIP was used to capture methylated DNA with immunoprecipitation (MeDIP). DNA was quantified and 2 μg (or total yield if less) was digested with MseI overnight at 37°C. Linkers (JW102-5'-GCGGTGACCCGG-GAGATCTGAATTC-3' and JW103-5'-TAGAATTCAGATC-3') were ligated at 16°C using T4 ligase overnight and the next day used as input for the MethylCollector (Active Motif, Carlsbard, CA) assay to isolate methylated and non-methylated fractions of DNA. The kit utilizes histidine-tagged MeBP2 (methyl-binding protein 2) and magnetic bead separation. The isolated methylated and non-methylated DNA from each sample (as little as 5 ng) was then amplified in a series of PCR reactions following the mammalian ChIP on ChIP protocol. The input DNA was labeled with Cy3-dUTP and the methylated DNA with Cy5-dUTP and then immediately applied to Agilent's 2 × 244 K Human Promoter Tiling Arrays for 40 hours at 65°C. The arrays were scanned using a Gene Pix 4000B scanner (Molecular Devices, Sunnyvale, CA) with GenePix Pro software version 6.1 and extracted using Agilent's Feature Extraction software version 188.8.131.52. The data was annotated using Agilent's ChIP Analytics software version 4.0. Normalization was carried out using a blank subtraction model and statistical stringency (p-value) between 0.01-0.05 was applied using a Whitehead Per-Array Neighbourhood Analysis. This analysis allowed for the determination of differentially methylated genes between non-invasive and invasive cells. Ingenuity core analysis was carried out to determine which pathways are of functional significance based on the gene lists identified http://www.ingenuity.com/. Genomatix software was used to determine transcription factor binding sites (matrix). A perfect match to the matrix gets a score of 1.00 (each sequence position corresponds to the highest conserved nucleotide at that position in the matrix), a "good" match to the matrix usually has a similarity of >0.80.
Mismatches in highly conserved positions of the matrix decrease the matrix similarity more than mismatches in less conserved regions.
Methylation Specific polymerase chain reaction (MSP-PCR)
A total of 1 μg of DNA extracted from total (parental) DU145 and LNCaP cells was bisulfite modified using the EpiTect Bisulfite kit from Qiagen. PCR was performed using Platinum Taq Polymerase (Invitrogen) and 200 ng of either genomic or bisulfite treated DNA. The PCR method utilized was 94°C for 2 minutes, then 35 cycles (94°C for 30 seconds, 55°C for 30 seconds and 72°C for 1 minute) with a final extension of 10 minutes at 72°C. The unmethylated primers however were run with an annealing temperature of 42°C since their melting temperature values were drastically different from their methylated counter part. A portion of the PCR product was run on a 1% agarose gel containing ethidum bromide.
hBMX-Forward 5'- TGGTGAGACATCATGTGTTCCATT-3';
hBMX-Reverse 5'- ATGCCCTCAGTTGAGAACCACTGT-3';
hSOX1- Reverse 5'-TCCGCTTCCTCCGTAGGTGATAAA-3'
hBMX-Forward 5'- TGGTGAGATATTATGTGTTTTATT-3';
hBMX-Reverse 5'- ATGTTTTTAGTTGAGAATTATTGT-3';
Quantitative real time polymerase chain reaction (QRT-PCR)
Total RNA was isolated using TRIzol (Invitrogen Corporation, Carlsbad, CA). RNA from 'top' cells was isolated using a cell pellet acquired from trypsinizing cells from one membrane after bottom cells were removed with a cotton swab. Conversely, RNA from the bottom cells was isolated by combining three membranes where the top cells were removed using a cotton swab. The membranes were pooled and placed in TRIzol for 10 minutes at room temperature, and the conventional procedure for isolation of RNA was then followed. To increase the yield of RNA, 5 μg of linear acrylamide (Ambion, Austin, TX) was added prior to precipitation of RNA with isopropanol. Additionally to increase overall yield, 100 ng of RNA was amplified using the MessageAmp aRNA Amplification Kit (Ambion, Austin, TX). cDNA was prepared using the SuperScript®III First-Strand Synthesis System (Invitrogen Corporation, Carlsbad, CA). Quantitative real time polymerase chain reaction (qRT-PCR) analysis was performed using a StepOne Real-time PCR machine (Applied Biosystems, Foster City, CA) with TaqMan Gene Expression Assay reagents and probes (Applied Biosystems). A total of 4 μL of cDNA was used in a 20 μL reaction resulting in a 1:5 dilution. The following FAM labeld human probes were used: BMX (Hs00174139_m1), IRX3 (Hs00273561_s1), SOX1 (Hs01023894_m1), MCL-1 (Hs00172036_m1), MYC (Hs00153408_m1), STAT3 (Hs01047580_m1), SURVIVIN (Hs00977611_g1) and 18S rRNA (Hs99999901_s1). Relative fold induction of mRNA was compared between non-invasive and invasive cells using the Delta-Delta CT method of quantitation, and 18S rRNA was used as a loading control.
shRNA of Bmx and Sox1
The Trans-Lentiviral pTRIPZ system from Open Biosystems (Huntsville, AL) was used to introduce shRNA against BMX (Clone ID: V2THS_150067) and SOX1 (V2THS_197330) along with a non-silencing control vector. The vectors were transfected into HEK239T cells which were seeded in serum-free media at 60% confluency in 10 cm2 dishes using the Arrest-In reagent provided in the kit. The cells were transfected for 6 hours and then replaced with complete media. After 24 and 48 hours lentiviral supernatants were harvested, spun at 1500 rpms, and filtered using a 0.45 μM filter to clear them. The viral titer was mixed 1:1 with DU145 media and placed on sub-confluent DU145 cells for 4-6 hours and changed to complete media. The next day media containing 1 μg/mL of doxycycline (Sigma) was added to ensure efficient transfection/infection has occurred. Efficient transfection was observed using a TET inducible TurboRFP (red fluorescent protein) upstream of the shRNA that appears red upon successful infection. The cells were selected for 2 weeks in 1 μg/mL of puromycin (Sigma). Single cell clones were then generated and lowered expression was confirmed using Western blotting.
Western Blotting and sub-cellular fractions
Total cell lysates were prepared using RIPA buffer (Sigma) and sub-cellular fractions using the NE-PER Nuclear Protein Extraction Kit (Thermo Scientific, Rockford,IL). Samples were loaded onto a 4-20% Tris-glycine gel and transferred to a PVDF membrane. The membranes were blocked at room temperature for 45 minutes in 5% non-fat milk in TBS-Tween (0.05%). Primary antibodies were as follows: BMX (Abcam-59360), pBMX (Cell Signaling-3211S), STAT3 (Santa Cruz-SC482), pSTAT3/Tyr705 (Cell Signaling-9131S), SOX1 (Cell Signaling 4194S) and Actin (Abcam-8227-50) and incubated overnight at 4°C. The membrane was washed 3× for 10 minutes each using TBS-T (0.1%). Secondary antibody was applied for 1 hour at room temperature (infrared goat-anti rabbit or mouse in the 800 channel) and washed. The membrane was developed using the Odyssey from Licor (Lincoln, NE). Protein loading was normalized using actin as a control. Densitometry analysis was performed using ImageJ (NIH, Bethesda, MD).
Cells were seeded overnight in a 96 well plate in 100 μL of regular media at a density of 2000 cells per well. Cell proliferation was measured using the CellTiter-Glo assay from Promega on Day 1, 3, 5 and 7 using 100 μL of reagent and an incubation time of 20 minutes. The relative luciferase units (RLU) were quantified using a Tecan Infinite 200 plate reader.
Prostatosphere Formation Assays
LNCaP and DU145 cells were seeded at 1000 cells per mL in replacement media SCM supplemented with KO Serum Replacement (Invitrogen) for LNCaP or B27 (Invitrogen) for DU145 cells in non-adherent 6 well plates coated with Hydrogel (Corning Life Sciences, Chemlsford, MA). The prostatospheres were generated for 5-7 days and then quantified or RNA extracted.
Staining of invasive or non-invasive cells was performed directly on the Matrigel membrane. Duplicate invasion chambers were used for each antibody; one each for staining invasive cells or non-invasive cells. Cells not being stained were removed from each insert, and cells of interest were fixed to the membrane in 4% para-formaldehyde for 15 minutes at 25°C and permeabilized with 0.5% saponin in PBS for 15 minutes at 25°C followed by a series of washes with PBS. Non-specific antibody binding sites were blocked for 15 minutes with 1% BSA in PBS containing 0.1% Tween-20 (PBS-T). Cells were incubated with either anti-pBMX antibody in PBS-T, SOX1 (Cell Signaling, Danvers, MA), or pSTAT3 (Millipore/Upstate Technologies, Billerica, MA (4°C, overnight). Following 3× PBS-T washes, infrared goat anti-rabbit Alexa 488 (Molecular Probes, Carlsbad, CA) was added for 1 hour at 25°C using a 1:500 dilution in PBS-T and again washed, then air-dried. Membranes were mounted on glass slides with Vectashield containing DAPI (Vector Laboratories, Burlingame, CA). Cells were visualized with a Zeiss-510 L5 confocal microscope where separate images were obtained for Alexa-488 and DAPI fluorescence, as well as overlays and 10 slice Z-stacks. Images were analyzed using the Zeiss LSM5 Image Browser (version 184.108.40.206) and further prepared in Adobe Photoshop CS. "Non-invasive" cells were stained on the topside of the membrane, while "invasive cells" were stained on the underside of the membrane. Controls using the secondary antibody and no primary antibody indicated that little, if any, fluorescence was contributed by non-specific binding of this antibody (data not shown).
Protein was extracted using RIPA buffer (Sigma) and lysates were incubated with either SOX1, STAT3 or BMX (same antibodies used in Western Blotting) overnight at 4°C with rotation. The next day Protein A sepharose beads were added to the lysate and incubated for 3 hours with rotation at 4°C. The lysate was then spun at 13,000 rpms in a benchtop centrifuge and washed 3× with RIPA buffer. Before loading on a 4-20% Tris-Glycine SDS-Page gel (Invitrogen) 2× loading buffer was added and upon completion the gel was transferred to a PVDF membrane. The membrane was blocked for 45 minutes using 5% non-fat milk in TBS-T (0.1%). The membrane was then incubated overnight at 4°C using either primary antibodies SOX1 or STAT3 diluted in blocking buffer to confirm a direction interaction. The membrane was washed 3× for 10 minutes each using TBS-T (0.1%). Secondary antibody was applied for 1 hour at room temperature (infrared goat-anti-rabbit in the 800 channel) and washed. The membrane was developed using the Odyssey from Licor. Protein loading was normalized using actin from pervious Westerns.
The Licor EMSA buffer kit was used according to the manufacturer's instructions. Infrared (IR) and unlabeled STAT3 oligos were ordered from IDT and used at 0.625 fmoles/reaction.
Wildtype probes (WT): (800-IR channel and unlabeled)
Mutant probes (MU): (700-IR channel)
Mutant oligos and unlabled wildtype oligos were used at 200-fold molar excess. A total of 20 μg of nuclear protein extract was incubated with 1× binding buffer (100 mM Tris, 500 mM KCl, 10 mM DTT; pH 7.5), Poly (dl·dC) 1 μg/μL (in 10 mM Tris, 1 mM EDTA, pH 7.5), 25 mM DTT/2.5% Tween-20, 1% NP-40, 100 mM MgCl2, and 50% glycerol for 20 minutes at room temperature shielded from light. For supershift experiments, extracts were pre-incubated with 5 μg of STAT3 antibody at 4°C for 30 minutes. DNA/protein complexes were visualized on a native 6% Tris-Borate-EDTA polyacrylamide gel. Gels were immediately removed from cassettes and scanned using the Odyssey in both the 700 and 800 channels.
Meta-analysis on patient databases
Oncomine and Gene Expression Omnibus (GEO) databases were queried to identify associations between genes. GEO database is available at http://www.pubmed.org (GEO profiles) and provides raw expression data from several gene expression arrays. Oncomine 4.2 database analysis tool is available with a subscription at http://www.oncomine.org Selected data was compared for gene expression levels in prostate primary tumor samples as well as their respective metastatic specimens. Data have been selected from  because this study was an integrated molecular profiling of gene expression in prostate cancer samples. In this work, a significant concordance between expression of Sox1 and Stat3 mRNA was found to correlate with the aggressiveness of the sample.
All statistical calculations were performed using GraphPad Prism Version 5. Comparisons between groups were carried out using either a Student's pair-wise t-test, or a One or Two-way ANOVA with a Bonferroni post-test wherever each test was applicable. Error bars represent the Standard Error of the Mean (SEM) and each experiment has been completed at least twice with samples in triplicate.
Identification of differentially methylated genes in invasive sub-populations of cells
Summary of genes methylated within the non-invasive LNCaP and DU145 cell lines
Verification of methylation array data
Functional role of Bmx and Sox1 during invasion
Role of SOX1 during differentiation
In addition to the method presented here, prostate TICs (tumor initiating cells) can also be isolated by culturing total cells in SCM where structures called prostatospheres are generated [18, 23–25]. The prostatospheres are multicellular globes that develop from cells that survive anchorage-independent conditions in vitro, and are frequently used when analyzing the ability of TICs to self-renew or differentiate upon the addition of serum. Using this assay as a model, a greater number of prostatospheres were isolated from DU145 NS cells compared to shSOX1 cells (Additional File 3, Figure S1A and B). When invasive DU145 cells were isolated and cultured in SCM, prostatospheres were maintained for up to 3 passages (Additional File 3, Figure S1C) and if these cells were further cultured in the presence of 1% human serum (Additional File 3, Figure S1C), the vector control (NS) cells rapidly differentiated and proliferated, while the shSOX1 cells did not (Additional File 3, Figure S1D). These observations suggest that not only does Sox1 play a role in regulating invasion, but it can also regulate the maintenance of 'stem-ness' in culture.
Ingenuity pathway analysis defines pathways of differentially methylated genes within invasive sub-populations of cells
Each data set of differentially methylated genes was then extracted and uploaded to the Ingenuity server to identify common gene pathways that are regulated during the process of invasion. The most conserved functional pathways between the cell lines are cellular development, cell growth and proliferation, as well as organismal development, nervous system development and function, and tissue development (Additional File 4, Table S3). The full list from the Ingenuity pathway analysis is also included (Additional File 5, Figure S2A and S2B). Additionally, the IL-6 signaling pathway involving STAT3 had a significant number of contributing methylated genes, a pathway recently found to play a significant role in cancer stem cell regulation [26–34] (Additional File 6, Figure S3A).
Inhibitor studies further determine the role of IL-6/STAT3 pathway in invasion
Direct interaction between the differentially methylated SOX1 and STAT3
Since inhibition of STAT3 demonstrated such a profound effect on invasion toward SCM, we questioned its involvement with the epigenetically regulated targets. Although we did not observe methylation of Stat3 itself, in both cell lines, the mRNA expression of Stat3 was increased (p-value < 0.03) when comparing invasive cells to their non-invasive counterpart (Figure 5B). Protein expression of pSTAT3 was also found to be increased in the invasive cells (Figure 5C). Since both SOX1 and STAT3 are known to act as transcriptional activators after forming protein complexes with other proteins [35–40], and BMX is known to activate STAT3 itself , we determined whether STAT3 directly interacts with either SOX1 or BMX. An interaction between SOX1 and STAT3 was observed (Figure 5D), however not between STAT3 and BMX (Figure 5D). In addition, a significant decrease in the expression of activated pSTAT3 was seen in both sub-cellular fractions of the BMX and SOX1 shRNA infected cells (Figure 5E). However, there was no change in total expression of STAT3. Additionally, a significant decrease in STAT3 DNA binding activity was observed in both BMX and SOX1 shRNA infected cells (Figure 5F). Overall, we see an interaction between SOX1 and STAT3, and upon loss of either BMX1 or SOX1 expression we observe a loss of STAT3 activation.
In order to determine what might be regulating the increased expression of Stat3 and Sox1, transcription factor binding sites were analyzed using Genomatix software. In both the Stat3 and Sox1 promoters there are a number of overlapping binding sites for transcription factors with a significant matrix value such as GATA-binding factors, RNA polymerase II transcription factor IIB (TFIIB), NeuroD/Beta2, TALE homeodomain class recognizing TG motifs, TCF11 transcription factor otherwise known as Nrf2, Nkx homeodomain factors, and finally the Zinc finger transcription factor RU49 also called Zipro1 (Additional File 7, Table S4). With this information, we can begin to understand why the methylation of Sox1 could serve as a master regulator of CSC invasion, thereby controlling its potential to undergo EMT and further metastasize.
Additional analysis using the GEO database determined that both Sox1 and Stat3 are expressed at higher levels in metastatic prostate cancer tissues and not Bmx (Figure 6C and 6D). Overall, we demonstrate that SOX1 is an epigenetically regulated target involved in the progression of prostate cancer, and is involved in signaling via the STAT3 pathway.
The process of epigenetic regulation by DNA methylation involves covalent modification of cytosine nucleotides at the C5 position in specific areas of CpG dinucleotides. The majority of methylated CpG dinucleotides are present in heterochromatic regions, and thus are unexpressed in the genome . The process of methylation in mammals evolved as a method of silencing genes when their expression is not required. For example, the process of genomic imprinting involves DNA methylation where one allele of a gene, either maternal or paternal, is silenced . This process only affects a few hundred genes within the genome, most of which encode for genes that regulate embryonic and neonatal growth . Likewise, a number of CpG islands on one X chromosome are methylated during a process called X-chromosome inactivation . This process ensures an equal amount of gene expression between males and females.
Using this model of invasion, we currently have developed a method to analyze differences in global CpG promoter methylation between total prostate cancer cells and their invasive population using promoter tiling arrays from Agilent. We identified a small subset of genes which were found to be differentially methylated between non-invasive and invasive LNCaP and DU145 cell lines. The results were highly intriguing because the majority of the genes normally function during human development (Additional File 4, Table S3). Based on previous data, these invasive cells demonstrated characteristics of true cancer stem cells (CSCs) . It is becoming more evident that CSCs are not governed by the same type of genetic regulation as normal stem cells, and arguably may be an epithelial cell that has up-regulated pathways that have been previously observed in true stem cells. To determine the epigenetic profile of these invasive prostate cancer cells and putative TICs, we determined which genes are differentially methylated.
The appearance of Sox1 as one epigenetically regulated target presented the most interesting finding of this investigation. SOX proteins are transcription factors that are key regulators of determining neuronal cell fate, not only mammals, but also in Drosophila, Xenopus, and avian models . Recently, much attention has been focused on these transcription factors since ectopic expression of Sox2 along with Oct3/4, Klf4 and Myc have been shown to reprogram murine fibroblasts to pluripotency, which in turn yields induced pluripotent stem (iPS) cells . In our model, when expression of SOX1 was decreased in DU145 cells using shRNA, there was a significant reduction in invasion toward our stem cell media termed SCM (Figure 4D). Although SOX1 has yet to be implicated as a regulator of aggression in prostate cancer, it has been implicated as a marker of CSCs in breast cancer. Using either CD44+/CD24- or CD133+ cells isolated from Brca1-deficient mouse mammary tumors, expression of Sox1 was found to be significantly higher in these cells when compared to their counterparts . In fact, expression of Sox1 was found to be 19.2-fold higher in CD44+/CD24- compared to CD44-/CD24+ cells, which represented the greatest change in any gene from this analysis .
The appearance of Bmx (also referred to as Etk) as a differentially methylated target was also interesting, yet not surprising, since this protein is a well-known regulator of prostate cancer. BMX is a family member of the Tec family of non-receptor tyrosine kinases that are predominately expressed in cells of hematopoietic origin, yet recently has also been shown to be expressed in arterial endothelium and a variety of epithelial cells [21, 39, 47, 48]. Although BMX has a role in the formation of leukemia [21, 49], our research is the first to demonstrate that BMX may play a significant role in the regulation of prostate cancer invasion and TICs. Although our shRNA studies against BMX did not demonstrate significant differences in invasion toward SCM, we were able to inhibit invasion of DU145 cells using the Tec family kinase inhibitor LFM-A13 without affecting normal cell proliferation (Additional File 6, Figure S3B), suggesting that this family of kinases may be indeed involved in metastasis.
After uploading our extensive list of differently methylated genes into the Ingenuity pathway analysis software, we observed that a number of the genes were members of the IL-6/STAT3 pathway. We tested a number of inhibitors of the IL-6 pathway for their ability to block invasion toward SCM. Small and non-significant effects of invasion were seen when inhibitors for MEK and JAK pathways, as well as a neutralizing antibody to IL-6 itself (Figure 5A). However, significant effects were seen using a PI3K inhibitor and a STAT3 inhibitor (Figure 5A). The role of PI3K signaling in prostate CSC regulation has been characterized, thus this observation is not too surprising . The most pronounced effect, however, was observed with the STAT3 inhibitor Stattic. This drug inhibits binding of a phosphotyrosine-containing peptide derived from the gp130 receptor to the STAT3 SH2 domain with IC50 value of 5.1 ± 0.8 μM after 1 hr of incubation at 37°C . The role of STAT3 in cancer progression has been known for sometime [52–56], and its role in CSC regulation has only recently been investigated. Higher levels of STAT3 have been demonstrated in CSCs isolated from liver, bone, cervical and brain cancers [26, 27, 29, 57–59], and furthermore treatment of putative glioblastoma stem cells (GBM-SC) with Stattic results in a dramatic reduction in their formation . Although the Stat3 gene itself was not methylated in any of our studies, qRT-PCR analysis demonstrated that compared to non-invasive cells, the invasive cells had a significant increase in expression of Stat3 (Figure 5B) and ICC detected an increase in active protein as well (Figure 5C). However, as seen in Figure S3B, there was a significant reduction in cell proliferation with Stattic treatment. To determine if this was the reason why we observed such a significant reduction in invasion, we took the remaining cells which survived treatment and further placed them through an invasion assay. The cells were unable to invade toward SCM, indicating that the cells resistant to Stattic-induced apoptosis were still sensitive at inhibiting invasion by lowering STAT3 (data not shown). A similar result was observed in the GBM-SCs, since different isolates of the cells responded differently to treatment with Stattic. The authors concluded that GBM-SCs derived in serum respond to Stattic by undergoing apoptosis, however in those derived using stem cell media they do not . They state that this could be a result of certain GBM-SC lines being more differentiated, and are thus more sensitive to STAT3 inhibition.
Since inhibition of SOX1 with shRNA and BMX ultimately with LFM-A13 (data not shown, but LFM-A13 inhibited IL-6 mediated activation of BMX in LNCaP cells) decreased invasion toward SCM, we sought to determine if an interaction might be occurring between these differentially methylated genes and STAT3. To test this, an IP was performed to see if either BMX or SOX1 directly interact with STAT3. We found that only SOX1 could directly interact with STAT3 and not BMX (Figure 5D), and this interaction occurs in both the cytoplasm and the nucleus. In these sub-cellular fractions, we still see an association between SOX1 and STAT3 in shSOX1 cells since expression of the protein was not fully ablated (Figure 4B). Interestingly, decreased expression of either BMX or SOX1 does result in significantly less active STAT3 (Figure 5E) and a decrease in its DNA binding activity (Figure 5F). This observation is not too surprising since BMX has been shown to regulate such cellular processes as differentiation, motility, invasion, apoptosis, and more recently, when inhibited, a delay in tumor growth [22, 60–66]. Specifically, within the prostate, BMX is up-regulated in tumors from both mouse and human specimens compared to benign tissues, and when over-expressed in cell lines, led to an increase in proliferation and elevated levels of AKT and STAT3 . Albeit having a role in the formation of leukemia [21, 49], our research is the first to demonstrate that BMX may play a significant role in the regulation of prostate CSCs.
Both STAT3 and SOX1 are transcription factors that regulate cell fate and differentiation; however a direct interaction between these proteins has never been identified. Future studies will be needed to determine what protein domains of each molecule are important for this interaction, as well as which promoters these transcription factors are regulating. However, the Oncomine and GEO data further support the observation that expression of both Sox1 and Stat3 are key genes regulating the progression of prostate cancer (Figure 6C and 6D). Regulation of Sox1 and Stat3 expression could occur coordinately since within their promoters they both contain transcription factor binding sites for NeuroD, TALE containing proteins, TCF11, and Nkxs (Additional File 7, Table S4). The TCF family of transcription factors regulates many patterns of development and activation of the TCF/LEF promoters. Recently, the Wnt proteins have been shown to regulate the 'stemness' of CSCs [67–70]. Additionally, expression of Nkx factors are required for neuronal cell fate, and interestingly, Nkx 2.2, Nkx 6.1 and Irx3, a NKX target, are also methylated in our study (Table 1) .
Overall, our data demonstrates that Sox1 is methylated in two prostate cancer cell lines, LNCaP and DU145, and two short-term primary prostate cancer cultures, PCSC1 and PCSC2, yet not methylated in the invasive compartment of these cells. The expression of Sox1 was found to be correlated with increased levels of Stat3 in our invasive cells, and to directly interact with the protein product as well. Finally, both Sox1 and Stat3 were found to have increased expression in relation to the progression of prostate cancer in humans. Using our in vitro method to investigate invasion we can begin to understand which genes are epigenetically regulated in the invasive putative CSC population. The process of epigenetic regulation is complex, but we have begun to unravel it in these invasive cells from the prostate.
This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract N01-CO-12400, and supported [in part] by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
The authors would also like to thank Dr. Stephanie Cabarcas from the lab for extensive editing of this manuscript.
- Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003, 100: 3983-3988. 10.1073/pnas.0530291100PubMed CentralView ArticlePubMedGoogle Scholar
- Graziano A, d'Aquino R, Tirino V, Desiderio V, Rossi A, Pirozzi G: The stem cell hypothesis in head and neck cancer. J Cell Biochem. 2008, 103: 408-412. 10.1002/jcb.21436View ArticlePubMedGoogle Scholar
- Cariati M, Purushotham AD: Stem cells and breast cancer. Histopathology. 2008, 52: 99-107. 10.1111/j.1365-2559.2007.02895.xView ArticlePubMedGoogle Scholar
- Kasper S: Exploring the Origins of the Normal Prostate and Prostate Cancer Stem Cell. Stem Cell Rev. 2008, 4: 193-201. 10.1007/s12015-008-9033-1View ArticlePubMedGoogle Scholar
- Takaishi S, Okumura T, Wang TC: Gastric cancer stem cells. J Clin Oncol. 2008, 26: 2876-2882. 10.1200/JCO.2007.15.2603PubMed CentralView ArticlePubMedGoogle Scholar
- Lee CJ, Dosch J, Simeone DM: Pancreatic cancer stem cells. J Clin Oncol. 2008, 26: 2806-2812. 10.1200/JCO.2008.16.6702View ArticlePubMedGoogle Scholar
- Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, Mistree T, Thomas SB, Farrar WL: Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis. 2009, 26: 433-436. 10.1007/s10585-009-9242-2PubMed CentralView ArticlePubMedGoogle Scholar
- Yu SC, Bian XW: Enrichment of cancer stem cells based on heterogeneity of invasiveness. Stem Cell Rev. 2009, 5: 66-71. 10.1007/s12015-008-9047-8View ArticlePubMedGoogle Scholar
- Sarkar FH, Li Y, Wang Z, Kong D: Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir. 2009, 64: 489-500.PubMed CentralPubMedGoogle Scholar
- Hollier BG, Evans K, Mani SA: The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia. 2009, 14: 29-43. 10.1007/s10911-009-9110-3View ArticlePubMedGoogle Scholar
- Schmalhofer O, Brabletz S, Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009, 28: 151-166. 10.1007/s10555-008-9179-yView ArticlePubMedGoogle Scholar
- Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A: Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One. 2008, 3: e2888- 10.1371/journal.pone.0002888PubMed CentralView ArticlePubMedGoogle Scholar
- Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008, 133: 704-715. 10.1016/j.cell.2008.03.027PubMed CentralView ArticlePubMedGoogle Scholar
- Bailey JM, Singh PK, Hollingsworth MA: Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. J Cell Biochem. 2007, 102: 829-839. 10.1002/jcb.21509View ArticlePubMedGoogle Scholar
- Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, Kirchner T: Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs. 2005, 179: 56-65. 10.1159/000084509View ArticlePubMedGoogle Scholar
- Tsuji T, Ibaragi S, Shima K, Hu MG, Katsurano M, Sasaki A, Hu GF: Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res. 2008, 68: 10377-10386. 10.1158/0008-5472.CAN-08-1444PubMed CentralView ArticlePubMedGoogle Scholar
- Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ: Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 2005, 8: 393-406. 10.1016/j.ccr.2005.10.001View ArticlePubMedGoogle Scholar
- Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL: CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer. 2008, 98: 756-765. 10.1038/sj.bjc.6604242PubMed CentralView ArticlePubMedGoogle Scholar
- Huang DY, Lin YT, Jan PS, Hwang YC, Liang ST, Peng Y, Huang CY, Wu HC, Lin CT: Transcription factor SOX-5 enhances nasopharyngeal carcinoma progression by down-regulating SPARC gene expression. J Pathol. 2008, 214: 445-455. 10.1002/path.2299View ArticlePubMedGoogle Scholar
- Yamada Y, Tahara M, Miya T, Satoh T, Shirao K, Shimada Y, Ohtsu A, Sasaki Y, Tanigawara Y: Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer. 2008, 98: 1034-1038. 10.1038/sj.bjc.6604271PubMed CentralView ArticlePubMedGoogle Scholar
- Kaukonen J, Lahtinen I, Laine S, Alitalo K, Palotie A: BMX tyrosine kinase gene is expressed in granulocytes and myeloid leukaemias. Br J Haematol. 1996, 94: 455-460.PubMedGoogle Scholar
- Dai B, Kim O, Xie Y, Guo Z, Xu K, Wang B, Kong X, Melamed J, Chen H, Bieberich CJ: Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Res. 2006, 66: 8058-8064. 10.1158/0008-5472.CAN-06-1364View ArticlePubMedGoogle Scholar
- Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS, Hahm SA, Haider M, Head CS, Reiter RE: Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate. 70: 491-501.Google Scholar
- Mulholland DJ, Xin L, Morim A, Lawson D, Witte O, Wu H: Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res. 2009, 69: 8555-8562. 10.1158/0008-5472.CAN-08-4673PubMed CentralView ArticlePubMedGoogle Scholar
- Duhagon MA, Hurt EM, Sotelo-Silveira JR, Zhang X, Farrar WL: Genomic profiling of tumor initiating prostatospheres. BMC Genomics. 11: 324-Google Scholar
- Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, Eyler CE, Elderbroom J, Gallagher J, Schuschu J: Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells. 2009, 27: 2393-2404. 10.1002/stem.188PubMed CentralView ArticlePubMedGoogle Scholar
- Sherry MM, Reeves A, Wu JK, Cochran BH: STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells. 2009, 27: 2383-2392. 10.1002/stem.185PubMed CentralView ArticlePubMedGoogle Scholar
- Gao H, Priebe W, Glod J, Banerjee D: Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium. Stem Cells. 2009, 27: 857-865. 10.1002/stem.23View ArticlePubMedGoogle Scholar
- Tang Y, Kitisin K, Jogunoori W, Li C, Deng CX, Mueller SC, Ressom HW, Rashid A, He AR, Mendelson JS: Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci USA. 2008, 105: 2445-2450. 10.1073/pnas.0705395105PubMed CentralView ArticlePubMedGoogle Scholar
- Daheron L, Opitz SL, Zaehres H, Lensch MW, Andrews PW, Itskovitz-Eldor J, Daley GQ: LIF/STAT3 signaling fails to maintain self-renewal of human embryonic stem cells. Stem Cells. 2004, 22: 770-778. 10.1634/stemcells.22-5-770View ArticlePubMedGoogle Scholar
- Nichane M, Ren X, Bellefroid EJ: Self-regulation of Stat3 activity coordinates cell-cycle progression and neural crest specification. Embo J. 29: 55-67.Google Scholar
- Choi SC, Kim SJ, Choi JH, Park CY, Shim WJ, Lim DS: Fibroblast growth factor-2 and -4 promote the proliferation of bone marrow mesenchymal stem cells by the activation of the PI3K-Akt and ERK1/2 signaling pathways. Stem Cells Dev. 2008, 17: 725-736. 10.1089/scd.2007.0230View ArticlePubMedGoogle Scholar
- Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J, Witte ON: Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci USA. 107: 2610-2615.Google Scholar
- Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS, Hahm SA, Haider M, Head CS, Reiter RE: Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate. 2009, 70: 491-501.PubMed CentralGoogle Scholar
- Seguin CA, Draper JS, Nagy A, Rossant J: Establishment of endoderm progenitors by SOX transcription factor expression in human embryonic stem cells. Cell Stem Cell. 2008, 3: 182-195. 10.1016/j.stem.2008.06.018View ArticlePubMedGoogle Scholar
- Kan L, Israsena N, Zhang Z, Hu M, Zhao LR, Jalali A, Sahni V, Kessler JA: Sox1 acts through multiple independent pathways to promote neurogenesis. Dev Biol. 2004, 269: 580-594. 10.1016/j.ydbio.2004.02.005View ArticlePubMedGoogle Scholar
- Gao SP, Bromberg JF: Touched and moved by STAT3. Sci STKE. 2006, 2006: pe30- 10.1126/stke.3432006pe30PubMedGoogle Scholar
- Gerhartz C, Heesel B, Sasse J, Hemmann U, Landgraf C, Schneider-Mergener J, Horn F, Heinrich PC, Graeve L: Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation. J Biol Chem. 1996, 271: 12991-12998. 10.1074/jbc.271.22.12999View ArticlePubMedGoogle Scholar
- Wen X, Lin HH, Shih HM, Kung HJ, Ann DK: Kinase activation of the non-receptor tyrosine kinase Etk/BMX alone is sufficient to transactivate STAT-mediated gene expression in salivary and lung epithelial cells. J Biol Chem. 1999, 274: 38204-38210. 10.1074/jbc.274.53.38204View ArticlePubMedGoogle Scholar
- Saharinen P, Ekman N, Sarvas K, Parker P, Alitalo K, Silvennoinen O: The Bmx tyrosine kinase induces activation of the Stat signaling pathway, which is specifically inhibited by protein kinase Cdelta. Blood. 1997, 90: 4341-4353.PubMedGoogle Scholar
- Jones PA, Takai D: The role of DNA methylation in mammalian epigenetics. Science. 2001, 293: 1068-1070. 10.1126/science.1063852View ArticlePubMedGoogle Scholar
- Reik W, Collick A, Norris ML, Barton SC, Surani MA: Genomic imprinting determines methylation of parental alleles in transgenic mice. Nature. 1987, 328: 248-251. 10.1038/328248a0View ArticlePubMedGoogle Scholar
- Rugg-Gunn PJ, Ferguson-Smith AC, Pedersen RA: Status of genomic imprinting in human embryonic stem cells as revealed by a large cohort of independently derived and maintained lines. Hum Mol Genet. 2007, 16 (Spec No. 2): R243-251. 10.1093/hmg/ddm245View ArticlePubMedGoogle Scholar
- Wolf SF, Jolly DJ, Lunnen KD, Friedmann T, Migeon BR: Methylation of the hypoxanthine phosphoribosyltransferase locus on the human X chromosome: implications for X-chromosome inactivation. Proc Natl Acad Sci USA. 1984, 81: 2806-2810. 10.1073/pnas.81.9.2806PubMed CentralView ArticlePubMedGoogle Scholar
- Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ: Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008, 451: 141-146. 10.1038/nature06534View ArticlePubMedGoogle Scholar
- Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L: Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 2008, 10: R10- 10.1186/bcr1855PubMed CentralView ArticlePubMedGoogle Scholar
- Schmidt U, Boucheron N, Unger B, Ellmeier W: The role of Tec family kinases in myeloid cells. Int Arch Allergy Immunol. 2004, 134: 65-78. 10.1159/000078339View ArticlePubMedGoogle Scholar
- Ekman N, Lymboussaki A, Vastrik I, Sarvas K, Kaipainen A, Alitalo K: Bmx tyrosine kinase is specifically expressed in the endocardium and the endothelium of large arteries. Circulation. 1997, 96: 1729-1732.View ArticlePubMedGoogle Scholar
- Ekman N, Arighi E, Rajantie I, Saharinen P, Ristimaki A, Silvennoinen O, Alitalo K: The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner. Oncogene. 2000, 19: 4151-4158. 10.1038/sj.onc.1203763View ArticlePubMedGoogle Scholar
- Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, Schultz PG, Reddy VA: The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA. 2009, 106: 268-273. 10.1073/pnas.0810956106PubMed CentralView ArticlePubMedGoogle Scholar
- Schust J, Sperl B, Hollis A, Mayer TU, Berg T: Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 2006, 13: 1235-1242. 10.1016/j.chembiol.2006.09.018View ArticlePubMedGoogle Scholar
- Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud AI: Activated stat-3 in melanoma. Cancer Control. 2008, 15: 196-201.PubMedGoogle Scholar
- Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T: Stat3 promotes metastatic progression of prostate cancer. Am J Pathol. 2008, 172: 1717-1728. 10.2353/ajpath.2008.071054PubMed CentralView ArticlePubMedGoogle Scholar
- Torres-Roca JF, DeSilvio M, Mora LB, Khor LY, Hammond E, Ahmad N, Jove R, Forman J, Lee RJ, Sandler H, Pollack A: Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10. Urology. 2007, 69: 505-509. 10.1016/j.urology.2006.11.006View ArticlePubMedGoogle Scholar
- Sanchez-Ceja SG, Reyes-Maldonado E, Vazquez-Manriquez ME, Lopez-Luna JJ, Belmont A, Gutierrez-Castellanos S: Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma. Lung Cancer. 2006, 54: 163-168. 10.1016/j.lungcan.2006.07.012View ArticlePubMedGoogle Scholar
- Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K: Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 2003, 22: 319-329. 10.1038/sj.onc.1206122View ArticlePubMedGoogle Scholar
- Feng D, Peng C, Li C, Zhou Y, Li M, Ling B, Wei H, Tian Z: Identification and characterization of cancer stem-like cells from primary carcinoma of the cervix uteri. Oncol Rep. 2009, 22: 1129-1134.PubMedGoogle Scholar
- Wilson H, Huelsmeyer M, Chun R, Young KM, Friedrichs K, Argyle DJ: Isolation and characterisation of cancer stem cells from canine osteosarcoma. Vet J. 2008, 175: 69-75. 10.1016/j.tvjl.2007.07.025View ArticlePubMedGoogle Scholar
- Nilsson CL, Dillon R, Devakumar A, Shi SD, Greig M, Rogers JC, Krastins B, Rosenblatt M, Kilmer G, Major M: Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells. J Proteome Res. 9: 430-443.Google Scholar
- Abassi YA, Rehn M, Ekman N, Alitalo K, Vuori K: p130Cas Couples the tyrosine kinase Bmx/Etk with regulation of the actin cytoskeleton and cell migration. J Biol Chem. 2003, 278: 35636-35643. 10.1074/jbc.M306438200View ArticlePubMedGoogle Scholar
- Busby JE, Shih SJ, Yang JC, Kung HJ, Evans CP: Angiogenesis is not mediated by prostate cancer neuropeptides. Angiogenesis. 2003, 6: 289-293. 10.1023/B:AGEN.0000029409.94626.64View ArticlePubMedGoogle Scholar
- He Y, Luo Y, Tang S, Rajantie I, Salven P, Heil M, Zhang R, Luo D, Li X, Chi H: Critical function of Bmx/Etk in ischemia-mediated arteriogenesis and angiogenesis. J Clin Invest. 2006, 116: 2344-2355.PubMed CentralPubMedGoogle Scholar
- Pan S, An P, Zhang R, He X, Yin G, Min W: Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Mol Cell Biol. 2002, 22: 7512-7523. 10.1128/MCB.22.21.7512-7523.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Rajantie I, Ekman N, Iljin K, Arighi E, Gunji Y, Kaukonen J, Palotie A, Dewerchin M, Carmeliet P, Alitalo K: Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium. Mol Cell Biol. 2001, 21: 4647-4655. 10.1128/MCB.21.14.4647-4655.2001PubMed CentralView ArticlePubMedGoogle Scholar
- Tu T, Thotala D, Geng L, Hallahan DE, Willey CD: Bone marrow X kinase-mediated signal transduction in irradiated vascular endothelium. Cancer Res. 2008, 68: 2861-2869. 10.1158/0008-5472.CAN-07-5743View ArticlePubMedGoogle Scholar
- Tsai YT, Su YH, Fang SS, Huang TN, Qiu Y, Jou YS, Shih HM, Kung HJ, Chen RH: Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation. Mol Cell Biol. 2000, 20: 2043-2054. 10.1128/MCB.20.6.2043-2054.2000PubMed CentralView ArticlePubMedGoogle Scholar
- Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST: Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res. 2008, 68: 3655-3661. 10.1158/0008-5472.CAN-07-2940View ArticlePubMedGoogle Scholar
- Katoh Y, Katoh M: FGF signaling inhibitor, SPRY4, is evolutionarily conserved target of WNT signaling pathway in progenitor cells. Int J Mol Med. 2006, 17: 529-532.PubMedGoogle Scholar
- Bisson I, Prowse DM: WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res. 2009, 19: 683-697. 10.1038/cr.2009.43View ArticlePubMedGoogle Scholar
- Hurt EM, Chan K, Serrat MA, Thomas SB, Veenstra TD, Farrar WL: Identification of Vitronectin as an Extrinsic Inducer of Cancer Stem Cell Differentiation and Tumor Formation. Stem Cells. 2009, 28: 390-398.Google Scholar
- Briscoe J, Pierani A, Jessell TM, Ericson J: A homeodomain protein code specifies progenitor cell identity and neuronal fate in the ventral neural tube. Cell. 2000, 101: 435-445. 10.1016/S0092-8674(00)80853-3View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.